BeOne Medicines AG 6160.HK is expected to report results on August 6 for the period ending June 30 2025
LSEG's mean analyst estimate for BeOne Medicines AG is for a loss of 32 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for BeOne Medicines AG is HK$198.00, about 7.8% above its last closing price of HK$182.60
This summary was machine generated August 4 at 11:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.